BRIEF published on 12/17/2025 at 14:43, 1 month ago First Berlin Equity Research met à jour sa recommandation sur Cardiol Therapeutics, passant à « Acheter » avec un objectif de cours abaissé. Recommandation D'achat Ajustement Du Prix Cible Thérapeutique Cardiaque Étude ARCHER De Phase II Myocardite
BRIEF published on 12/17/2025 at 14:43, 1 month ago First Berlin Equity Research Updates Cardiol Therapeutics to "Buy" with a Lowered Target Price Buy Recommendation Target Price Adjustment Cardiol Therapeutics Phase II ARCHER Study Myocarditis
PRESS RELEASE published on 12/17/2025 at 14:38, 1 month ago Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): BUY First Berlin Equity Research updates BUY recommendation for Cardiol Therapeutics Inc., lowering price target to USD 7.80 based on positive Phase II ARCHER data on CardiolRx for acute myocarditis First Berlin Equity Research Buy Recommendation Acute Myocarditis Cardiol Therapeutics Inc. Phase II ARCHER Data
BRIEF published on 10/23/2025 at 12:56, 2 months 25 days ago Cardiol Therapeutics Secures Funding with USD 11.4 Million Private Placement Private Placement Clinical Trials Financial Outlook Cardiol Therapeutics Heart-Failure Therapy
BRIEF published on 10/23/2025 at 12:56, 2 months 25 days ago Cardiol Therapeutics obtient un financement avec un placement privé de 11,4 millions de dollars Placement Privé Essais Cliniques Cardiol Therapeutics Perspectives Financières Traitement De L'insuffisance Cardiaque
PRESS RELEASE published on 10/23/2025 at 12:51, 2 months 25 days ago Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): BUY First Berlin Equity Research updates Cardiol Therapeutics Inc with a BUY rating and USD 8.50 price target. The private placement secures funds for pivotal trials and new product development Private Placement Cardiol Therapeutics Inc First Berlin Equity Research BUY Rating USD 8.50 Price Target
BRIEF published on 08/12/2025 at 13:36, 5 months 5 days ago Cardiol Therapeutics : résultats de l'essai de phase II et perspectives boursières positives Cardiol Therapeutics Acheter Une Note CardiolRx Essai ARCHER De Phase II Myocardite Aiguë
BRIEF published on 08/12/2025 at 13:36, 5 months 5 days ago Cardiol Therapeutics: Phase II Trial Results and Positive Stock Outlook BUY Rating Cardiol Therapeutics CardiolRx Phase II ARCHER Trial Acute Myocarditis
PRESS RELEASE published on 08/12/2025 at 13:31, 5 months 5 days ago Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): BUY First Berlin Equity Research updates BUY recommendation for Cardiol Therapeutics Inc after positive phase II trial results for CardiolRx in acute myocarditis Cardiol Therapeutics Inc First Berlin Equity Research Phase II Trial CardiolRx Acute Myocarditis
BRIEF published on 04/23/2025 at 15:29, 8 months 24 days ago Cardiol Therapeutics Advances in Pivotal Phase III Study FDA Approval Cardiol Therapeutics Phase III Study Recurrent Pericarditis CardiolRxT
Published on 01/17/2026 at 02:20, 18 hours 12 minutes ago Core Critical Metals Announces a 1 for 2 Stock Split
Published on 01/16/2026 at 23:19, 21 hours 13 minutes ago Silver North Announces Further Upsize of Brokered LIFE Private Placement for Gross Proceeds of up to C$10.6 Million
Published on 01/16/2026 at 23:00, 21 hours 32 minutes ago Silver Spruce Resources Inc. Announces Grant of Options
Published on 01/16/2026 at 22:55, 21 hours 37 minutes ago Silver Spruce Resources Inc. Announces Closing of $976,000 Non-Brokered Private Placement
Published on 01/17/2026 at 13:59, 6 hours 32 minutes ago Turkiye Garanti Bankasi A.S.: Regarding the Sale of Non-Performing Loans Portfolio
Published on 01/17/2026 at 13:56, 6 hours 35 minutes ago Turkiye Garanti Bankasi A.S.: Redemption of the debt instrument at abroad within the Medium Term Note (MTN) program
Published on 01/16/2026 at 19:07, 1 day 1 hour ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 01/16/2026 at 18:36, 1 day 1 hour ago CPI PROPERTY GROUP – Completion of the Share Buy-back Offer
Published on 01/16/2026 at 18:12, 1 day 2 hours ago Westwing Group SE Trading Update: Westwing delivered a strong 9% GMV growth in Q4 2025 and significantly increased full-year 2025 guidance on adjusted EBITDA
Published on 01/16/2026 at 18:39, 1 day 1 hour ago Nombre total d'actions et droits de vote - décembre 2025
Published on 01/16/2026 at 18:39, 1 day 1 hour ago Number of shares and voting rights - December 2025 (In French only)
Published on 01/16/2026 at 08:53, 1 day 11 hours ago www.entech-se.com COMMUNIQUÉ DE PRESSE Entech remporte un contrat pour la construction de 400 MWh de stockage d’énergie (BESS) en partenariat avec Eiffage Énergie Systèmes
